| Title |
Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2013
|
| DOI | 10.2147/dddt.s42902 |
| Pubmed ID | |
| Authors |
Vinicius Marcondes Rezende, Ariane Rivellis, Mafalda Megumi Yoshinaga Novaes, Dalton de Alencar Fisher Chamone, Israel Bendit |
| Abstract |
Imatinib mesylate has been a breakthrough treatment for chronic myeloid leukemia. It has become the ideal tyrosine kinase inhibitor and the standard treatment for chronic-phase leukemia. Striking results have recently been reported, but intolerance to imatinib and noncompliance with treatment remain to be solved. Molecular monitoring by quantitative real-time polymerase chain reaction is the gold standard for monitoring patients, and imatinib blood levels have also become an important tool for monitoring. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Croatia | 1 | 4% |
| Hungary | 1 | 4% |
| United States | 1 | 4% |
| Unknown | 22 | 88% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 24% |
| Student > Ph. D. Student | 6 | 24% |
| Professor > Associate Professor | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Professor | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 4 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 20% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Chemistry | 3 | 12% |
| Social Sciences | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 4 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2013.
All research outputs
#22,778,604
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#1,757
of 2,270 outputs
Outputs of similar age
#187,233
of 210,144 outputs
Outputs of similar age from Drug Design, Development and Therapy
#35
of 43 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,144 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.